Codexis, Inc. (CDXS)
| Previous Close | 3.0900 |
| Open | 3.0200 |
| Bid | 2.9500 x 300 |
| Ask | 2.9800 x 100 |
| Day's Range | 2.9400 - 3.0300 |
| 52 Week Range | 1.5100 - 4.9100 |
| Volume | |
| Avg. Volume | 573,967 |
| Market Cap | 210.732M |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company’s exi
- GlobeNewswire
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applicationsREDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis’ life science enzyme portfo
- GlobeNewswire
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company’s 2024 I
